VRX
Valeant Pharmaceuticals International Inc
Valeant Pharmaceuticals International Inc historical holders
total: 14
Chou Associates Management Valeant Pharmaceuticals International Inc transactions over time
- Total transactions:
- 8
- New positions:
- 1
- Sold out:
- 1
- Added:
- 5
- Reduced:
- 1
- Held since:
- 2016 Q1
- Held for:
- 10 quarters
- Latest activity:
- 2018 Q3
Francis Chou has been an institutional investor in Valeant Pharmaceuticals International Inc (VRX) since 2016 Q1. According to 2026 Q1 report, Francis Chou doesn't hold any shares. The fund/company first acquired VRX in 2016 Q1, initially purchasing 976,843 shares. Since the initial investment, Chou Associates Management has made 7 more transactions in this position.
When did Francis Chou exit their VRX position?
Francis Chou no longer holds Valeant Pharmaceuticals International Inc (VRX). They sold off their entire position in 2018 Q3, closing out an investment that began in 2016 Q1.
When did Francis Chou first invest in VRX?
Francis Chou first invested in Valeant Pharmaceuticals International Inc (VRX) in 2016 Q1 at the reported quarter-end price of $26.33 per share, acquiring 976,843 shares in their initial purchase.
What is Francis Chou's average cost basis for VRX?
Based on historical transaction data, Francis Chou's estimated cost basis for Valeant Pharmaceuticals International Inc (VRX) is approximately $18.23 per share. This represents their average reported price* across all buy transactions.
Estimated cost basis*
- Weighted AVG buy price:
- $18.23
- Weighted AVG sell price:
- $21.67
VRX transactions history by Chou Associates Management
8 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2018 Q3
|
0.00%
|
$23.24
|
-100% (-1,648,992)
|
|||
|
2018 Q1
|
11.07%
|
$15.92
|
+1,006.77% (+1,500,000)
|
|||
|
2017 Q4
|
1.32%
|
$20.78
|
-95.12% (-2,904,851)
|
|||
|
2017 Q2
|
16.38%
|
$17.37
|
+29.74% (+700,000)
|
|||
|
2017 Q1
|
8.61%
|
$11.03
|
+20.04% (+393,000)
|
|||
|
2016 Q4
|
9.10%
|
$14.52
|
+35.53% (+514,000)
|
|||
|
2016 Q2
|
11.12%
|
$20.14
|
+48.11% (+470,000)
|
|||
|
2016 Q1
|
8.35%
|
$26.33
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.